Insider · CIK 0001875723
Jonathan Slonin
Files at PCRX (Pacira BioSciences, Inc.). First filing Nov 19, 2025, latest Mar 19, 2026.
Jonathan Slonin files SEC Form 4 as officer at PCRX (Pacira BioSciences, Inc.). Since Nov 19, 2025, Jonathan Slonin has reported 0 open-market buys worth $0 and 2 open-market sells worth $170k, the latest filed on Mar 19, 2026.
A track record needs three past buys with six months of prices behind them; Jonathan Slonin has 0, so none is measured yet.
The newest scored trade: sold $74k of PCRX on Mar 17, 2026, filed Mar 19, 2026, scored 11 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 2 sells worth $170k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
PCRX: Pacira BioSciences, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 11Weak | Pacira BioSciences, Inc. | $74k 3,261 shares | -1% | +15% from low-19% from high | |
| 13Weak | Pacira BioSciences, Inc. | $95k 3,960 shares | -2% | +44% from low-12% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 17, 2026 | PCRX Pacira BioSciences, Inc. | 3,040 0.01% of outstanding | $71k | Aug 17, 2026 | none |
| Mar 17, 2026 | PCRX Pacira BioSciences, Inc. | 3,261 0.01% of outstanding | $74k | Mar 17, 2026 | none |
| Nov 17, 2025 | PCRX Pacira BioSciences, Inc. | 3,960 0.01% of outstanding | $95k | Nov 17, 2025 | none |
| Jan 6, 2025 | PCRX Pacira BioSciences, Inc. | 879 0.00% of outstanding | $16k | Jan 6, 2025 | none |
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | PCRX Pacira BioSciences, Inc. | FTax withholding Common Stock | -4,728 | $22.32 | $106k | 218,912 | Jun 5, 2026 |
| Mar 17, 2026 | PCRX Pacira BioSciences, Inc. | SOpen-market sale Common Stock10b5-1 | -3,261 | $22.82 | $74k | 223,640 | Mar 19, 2026 |
| Feb 11, 2026 | PCRX Pacira BioSciences, Inc. | AGrant or award Common Stock | +54,546 | $0.00 | $0 | 226,901 | Feb 13, 2026 |
| Jan 30, 2026 | PCRX Pacira BioSciences, Inc. | FTax withholding Common Stock | -6,168 | $20.54 | $127k | 172,355 | Feb 3, 2026 |
| Jan 2, 2026 | PCRX Pacira BioSciences, Inc. | FTax withholding Common Stock | -381 | $24.46 | $9,319 | 178,523 | Jan 6, 2026 |
| Nov 17, 2025 | PCRX Pacira BioSciences, Inc. | SOpen-market sale Common Stock10b5-1 | -3,960 | $24.09 | $95k | 178,367 | Nov 19, 2025 |
| Aug 1, 2025 | PCRX Pacira BioSciences, Inc. | FTax withholding Common Stock | -315 | $22.07 | $6,952 | 182,327 | Aug 4, 2025 |
| Jun 3, 2025 | PCRX Pacira BioSciences, Inc. | FTax withholding Common Stock | -5,084 | $26.40 | $134k | 181,960 | Jun 5, 2025 |
Questions about Jonathan Slonin
Answered from the filings on this page, as of the latest one.
Is Jonathan Slonin buying or selling?
In the last 12 months Jonathan Slonin reported 0 open-market buys worth $0 and 2 open-market sells worth $170k on SEC Form 4; the latest was sold $74k of PCRX on Mar 17, 2026. Grants, option exercises and tax withholding are not counted.
How did Jonathan Slonin's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jonathan Slonin has 0.
Where does Jonathan Slonin file Form 4?
Jonathan Slonin has filed Form 4 at PCRX (Pacira BioSciences, Inc.) as Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.